Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations.

Guijosa, A., Tsakmaklis, N., Kobs, M., Kofides, A., Guerrera, M. L., von Keudell, G., Branagan, A., Hunter, Z. R., Treon, S. P., Sarosiek, S., & Castillo, J. J. (2026). Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations.. Leukemia, 40(3), 671-675.
Last updated on 04/02/2026
PubMed